Codexis to Participate in Cantor Global Healthcare Conference
Codexis (NASDAQ:CDXS), a provider of enzymatic solutions for therapeutic manufacturing, announced its participation in the upcoming Cantor Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Codexis (NASDAQ:CDXS), a provider of enzymatic solutions for therapeutic manufacturing, announced its participation in the upcoming Cantor Global Healthcare Conference. The event will take place from September 3-5, 2025, in New York.
The company's management will engage in a fireside chat on September 4, 2025, at 3:55 pm ET. Investors can access a live webcast through Codexis's investor relations website, with a replay available for 90 days after the event.
Details
News Market Reaction – CDXS
On Aug 28, the day this news came out, CDXS closed 1.87% above the previous close.
Data tracked by StockTitan Argus for the Aug 28 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference, being held September 3-5, 2025, in New York, New York.
Management will participate in a fireside chat on Thursday, September 4, 2025, at 3:55 pm ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, https://ir.codexis.com. A replay will be archived for 90 days following the event.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis® manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
For More Information
Investor Contact
Georgia Erbez
650-421-8100
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.